Non-Interventional F-Two Isoprostane Trial (NIFTI) (NIFTI)
Recruitment status was: Recruiting
Each year in the United States alone, 300,000 persons are hospitalized for traumatic brain injury, with approximately one quarter dying. Despite advances in aggressive neurosurgical interventions, intensive care monitoring and overall supportive management, many of those who do "survive" do not fully recover and are left with a varying degree of permanent disability. It is therefore imperative that new methods of early interventions be explored.
One possible road to effective therapy is to examine the timing of secondary injury via a biological marker, to help guide the timing of treatment directed specifically at early oxidant injury. A more thorough understanding of how quickly oxidant injury occurs will allow us to direct appropriate therapies targeted directly at oxidant injury within what is currently thought to be a very narrow window of opportunity for intervention, possibly peaking within the first two hours after the initial injury.
Potential participants include patients between the ages of 18 and 50 years who are admitted to Parkland Memorial Hospital with a diagnosis of severe traumatic brain injury. Blood, urine, and CSF (if patient requires a clinically indicated ventriculostomy) will be collected over the first 5 days post-injury. Clinically-relevant patient progress, clinically required interventions, neuro-imaging results, and demographics will be tracked while the patient is hospitalized, with final neurological outcome measured at 3 months.
Traumatic Brain Injury
|Study Design:||Time Perspective: Prospective|
|Official Title:||Non-Interventional F-Two Isoprostane Trial|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00505908
|Contact: Jane G Wigginton, M.D.||email@example.com|
|Contact: Victoria S Warren, R.N.||firstname.lastname@example.org|
|United States, Texas|
|Parkland Memorial Hospital||Recruiting|
|Dallas, Texas, United States, 75235|
|Contact: Jane G Wigginton, M.D. 214-648-2917 email@example.com|
|Contact: Victoria S Warren, R.N. 214-648-9491 firstname.lastname@example.org|
|Principal Investigator: Jane G Wigginton, M.D.|
|Sub-Investigator: Christopher Madden, M.D.|
|Sub-Investigator: Ahamed Idris, M.D.|
|Sub-Investigator: Karla Saner, Ph.D.|
|Sub-Investigator: Lisa Halvorson, M.D.|
|Principal Investigator:||Jane G Wigginton, M.D.||University of Texas Southwestern Medical Center|